SMARCD2 Inhibitors

The chemical class of SMARCD2 inhibitors encompasses a range of compounds primarily characterized by their ability to indirectly influence the function of SMARCD2 through modulation of chromatin remodeling processes. These compounds do not target SMARCD2 directly but affect the cellular mechanisms and pathways that are crucial for its role in chromatin structure and gene expression. The primary mechanism of action for these inhibitors is the alteration of histone acetylation and DNA methylation states, which are key processes in chromatin remodeling and, consequently, in the regulation of transcription where SMARCD2 is involved.

Histone deacetylase inhibitors, such as Trichostatin A, SAHA (Vorinostat), MS-275 (Entinostat), and Belinostat, work by preventing the removal of acetyl groups from histone proteins. This alteration in histone acetylation can lead to changes in chromatin structure, potentially impacting the activity of chromatin remodeling complexes like the one involving SMARCD2. DNA methyltransferase inhibitors like 5-Azacytidine and Decitabine change the methylation pattern of DNA, another crucial factor in determining chromatin structure and gene expression. These changes in the epigenetic landscape can indirectly affect the function of SMARCD2 in chromatin remodeling.